Mirtazapine Flas Normogen

Mirtazapine, the active ingredient in Mirtazapine Flas Normogen, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It treats major depressive disorder in adult patients, helping to improve mood, sleep, and appetite.

GNH USA supplies Mirtazapine Flas Normogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Mirtazapine is indicated for depressive disorders, acting on noradrenergic and serotonergic pathways to alleviate symptoms.

- Major depressive disorder: reduces depressive symptoms and improves sleep and appetite in adults. - Depressive episodes with anxiety: alleviates both mood and anxiety components in patients. - Treatment‑resistant depression (adjunct): used alongside other antidepressants when response is inadequate.

Mirtazapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness or sedation - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis - Severe neutropenia - Hepatotoxicity

When prescribing Mirtazapine, clinicians should consider several precautionary measures.

- Assess psychiatric history: evaluate for suicidal ideation before initiating therapy. - Monitor weight: watch for significant weight gain during treatment. - Evaluate liver function: adjust use in patients with hepatic impairment. - Caution in elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Mirtazapine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome; require a 14‑day washout. - Potent CYP1A2 inhibitors (e.g., fluvoxamine): may increase plasma levels, leading to toxicity. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine, tamoxifen): altered metabolism may affect therapeutic outcomes. - Anticholinergic agents: may exacerbate dry mouth and constipation. - NSAIDs or anticoagulants: increased risk of bleeding when combined with platelet effects.